Carl Domino Inc Lowers stake in Amgen (AMGN)

Amgen (AMGN) : Carl Domino Inc reduced its stake in Amgen by 0.13% during the most recent quarter end. The investment management company now holds a total of 8,900 shares of Amgen which is valued at $1,462,448 after selling 12 shares in Amgen , the firm said in a disclosure report filed with the SEC on Oct 12, 2016.Amgen makes up approximately 1.39% of Carl Domino Inc’s portfolio.

Other Hedge Funds, Including , North Star Investment Management Corp. reduced its stake in AMGN by selling 2,335 shares or 12.05% in the most recent quarter. The Hedge Fund company now holds 17,046 shares of AMGN which is valued at $2,800,999. Amgen makes up approx 0.51% of North Star Investment Management Corp.’s portfolio. Contravisory Investment Management sold out all of its stake in AMGN during the most recent quarter. The investment firm sold 13 shares of AMGN which is valued $2,188.Simplex Trading reduced its stake in AMGN by selling 11,259 shares or 40.69% in the most recent quarter. The Hedge Fund company now holds 16,414 shares of AMGN which is valued at $2,749,345. Amgen makes up approx 0.36% of Simplex Trading’s portfolio.Arvest Bank Trust Division boosted its stake in AMGN in the latest quarter, The investment management firm added 25 additional shares and now holds a total of 1,495 shares of Amgen which is valued at $250,413. Amgen makes up approx 0.02% of Arvest Bank Trust Division’s portfolio.North Star Asset Management Inc reduced its stake in AMGN by selling 100 shares or 5.32% in the most recent quarter. The Hedge Fund company now holds 1,781 shares of AMGN which is valued at $297,854. Amgen makes up approx 0.03% of North Star Asset Management Inc’s portfolio.

Amgen closed down -3.99 points or -2.37% at $164.32 with 27,61,896 shares getting traded on Tuesday. Post opening the session at $167.82, the shares hit an intraday low of $163.51 and an intraday high of $167.82 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.